References
- Mousli M, Bronner C, Bueb JL, Tschirhart E, Gies JP, Landry Y. Activation of rat peritoneal mast cells by substance P and mastoparan. J Pharmac Exp Ther 1989; 250: 329–335.
- Payan DG, Brewster DR, Goetzl EJ. Specific stimulation of human T lymphocytes by substance P. J Immunol 1983; 131: 1613–5.
- Brunelleschi S, Tarli S, Giotti A, Fantozzi R. Priming effects of mammalian tachykinins on human neutrophils. Life Sci 1991; 48: PL1–5.
- Brunelleschi S, Vanni L, Ledda F, Giotti A, Maggi CA, Fantozzi R. Tachykinins activate guinea-pig alveolar macrophages: involvement of NK2 and NKi receptors. Br J Pharmacol 1990; 100: 417–20.
- Brunelleschi S, Guidotto S, Viano I et al. Tachykinin activation of human alveolar macrophages in tobacco smoke and sarcoidosis: a phenotypical and functional study. Neuropeptides 1996; 30: 456–64.
- Lotz M, Vaughan JH, Carson DA. Effects of neuropep-tides on production of inflammatory cytokines by human monocytes. Science 1988; 241: 1218–21.
- Kavelaars A, Broeke D, Jeurissen F et al. Activation of human monocytes via a non-neurokinin substance P receptor that is coupled to G; protein, calcium, phospholipase D, MAP kinase and IL-6 production. J Immunol 1994; 153: 3691–99.
- Levine JD, Clark R, Devor M, Helms C, Moskowitz MA, Bausbaum Al. Intraneural substance P contributes to the sever-ity of experimental arthritis. Science 1984; 226: 547–9.
- Lotz M, Carson DA, Vaughan JH. Substance P activa-tion of rheumatoid synoviocytes: neural pathway in the patho-genesis of arthritis. Science 1987; 235: 893–5.
- Devillier P, Weill BJ, Menkes CJ, Pradelles P, Renoux M. Elevated levels of tachykinin-like activity in joint fluid from patients with rheumatic inflammatory diseases. N Engl J Med 1986; 314: 1323.